Company Overview of Convergence Pharmaceuticals Limited
Convergence Pharmaceuticals Limited engages in the development of analgesics for the treatment of chronic pain. It offers CNV1014802, a small molecule state-dependent sodium channel blocker that exhibits potency and selectivity against the Nav1.7 sodium channel; and CNV1061436, a Phase I ready sodium channel blocker for the treatment of CNS disorders, including epilepsy and bipolar disorder. The company was founded in 2010 and is based in Cambridge, United Kingdom. As of February 12, 2015, Convergence Pharmaceuticals Limited operates as a subsidiary of Biogen Inc.
Babraham Research Campus
Cambridge, CB22 3AT
Founded in 2010
44 1223 755 501
44 1223 497 114
Key Executives for Convergence Pharmaceuticals Limited
Similar Private Companies By Industry
|Abbey Pharma Limited||Europe|
|Absynth Biologics Limited||Europe|
|Acacia Pharma Limited||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Convergence Pharmaceuticals Limited, please visit www.convergencepharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.